What is Nusano?
Nusano operates at the intersection of advanced physics and healthcare, positioning itself as a pivotal player in the medical radioisotope supply chain. The company is dedicated to solving the systemic supply instability that has long hindered the medical community's access to high-quality isotopes. By leveraging innovative production methodologies, Nusano aims to provide a reliable, consistent, and scalable source of radioisotopes for both clinical and industrial applications.
The company's market position is defined by its focus on industrial-scale production, which is essential for meeting the rising demand for precision medicine. Unlike traditional reactor-based production models, Nusano's approach emphasizes technological efficiency and supply chain resilience, ensuring that healthcare providers and commercial entities have uninterrupted access to the materials required for life-saving diagnostic and treatment procedures.
How much funding has Nusano raised?
Nusano has raised a total of $156M across 2 funding rounds:
Series A
$41M
Series C
$115M
Series A (2018): $41M, investors not publicly disclosed
Series C (2024): $115M led by Verily, The Wasatch Group, and S32
Key Investors in Nusano
Verily
Verily Life Sciences LLC is a U.S.-based healthcare technology company and subsidiary of Alphabet Inc., focused on improving health outcomes through data-driven research and digital health solutions.
The Wasatch Group
The Wasatch Group is a diversified investment firm with a focus on strategic capital allocation and long-term value creation across various industrial and commercial sectors.
S32
SISTEMA 32 specializes in integrated design solutions and functional infrastructure, bringing a unique perspective on operational efficiency and technological integration to their investment portfolio.
What's next for Nusano?
With the successful closure of this major enterprise-level funding round, Nusano is well-positioned to accelerate its commercialization strategy and expand its production footprint. The capital will likely be deployed toward scaling its proprietary technology, enhancing facility throughput, and strengthening its distribution networks to meet the global demand for medical isotopes. As the company transitions into this next phase of growth, the focus will remain on achieving operational excellence and establishing long-term partnerships with healthcare systems and industrial stakeholders. The strategic nature of this investment suggests that Nusano is not merely expanding its capacity but is actively reshaping the competitive landscape of the radioisotope market, setting a new standard for reliability and innovation in the life sciences sector.
See full Nusano company page
